At Integral Therapeutic, we bridge the gap between cutting-edge global science and local clinical needs. We are proud to be associated with the world’s leaders in molecular profiling and genetic diagnostics:
Caris Life Sciences: Pioneers in molecular profiling, providing the most comprehensive tumor analysis available.
Mayo Clinic Laboratories: Leveraging the diagnostic expertise of one of the world's highest-ranked medical institutions.
Gene Solutions: Leaders in accessible, high-accuracy liquid biopsy and multi-cancer early detection.
Myriad Genetics: Specialists in hereditary cancer risk and personalized medicine (BRCA/HRD testing).
S.N. Genes: Our partners in specialized genetic sequencing and actionable clinical reports.
MI Profile® is a comprehensive solution that assesses DNA, RNA, and proteins directly from tumor tissue, revealing a detailed molecular blueprint to help guide precise and individualized treatment decisions.
MI Tumor Seek Hybrid™
Advanced testing begins with Next-Generation Sequencing (NGS) using MI Tumor Seek Hybrid™. This single assay provides a deep analysis of over 23,000 genes by performing Whole Exome and Whole Transcriptome Sequencing, giving you a complete genomic picture.
Caris Life Sciences leverages cutting-edge CISH, Pyrosequencing, and AI-Predictive Algorithms, including Caris GPSai™ and Caris FOLFIRSTai®, to redefine precision medicine
Precision Diagnostics by Genes Solutions Singapore
Early Detection (SPOT-MAS 10): A simple blood test to detect early-stage cancer by identifying circulating tumor DNA (ctDNA) signatures.
Comprehensive Profiling (K-4 CARE): Integrating DNA and RNA profiling with high-sensitivity MRD tracking to provide a 360-degree view of the tumor landscape.
Personalized Monitoring (K-TRACK): Stay ahead of cancer with custom ctDNA tracking that monitors how well a treatment is working and detects relapse months before imaging.
Therapeutic Support: Partnering with life sciences to provide the real-world evidence and tailored data needed for the next generation of cancer therapies.